Neurocrine Biosciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Neurocrine Biosciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Neurocrine Biosciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Neurocrine Biosciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Neurocrine Biosciences Inc (Neurocrine) is a biopharmaceutical company that discovers, develops and markets neurological drugs. The company is engaged in discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company’s lead product Ingrezza, is a vesicular monoamine transporter 2 (VMAT2) inhibitor to treat adults with tardive dyskinesia and chorea associated with Huntington’s disease. Neurocrine Biosciences' products are used by patients with under-addressed medical conditions, primarily in the healthcare industry. Neurocrine also conducts clinical trials and studies for diseases such as movement disorders, epilepsy, and congenital adrenal hyperplasia, among others. The company distributes its products through a network of specialty pharmacy providers and wholesale distributors. The company operates primarily in the United States and targets markets in neurology, psychiatry, and endocrinology. Neurocrine Biosciences is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
6027 Edgewood Bend Court, San Diego, California, 92130
Website
www.neurocrine.com
Telephone
1 858 6177600
No of Employees
2,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NBIX (NASD)
Revenue (2024)
$2.9B
21.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
40.2%
(2024 vs 2023)
Market Cap*
$15.6B
Net Profit Margin (2024)
XYZ
15.5%
(2024 vs 2023)
* As of and is in US$
Neurocrine Biosciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Ongentys (Opicapone) Capsules | Ingrezza |
| Ingrezza (Valbenazine) Capsules | Ongentys |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In May, the company acquired Soleno Therapeutics, Inc for US$2.9 billion. |
| 2026 | Contracts/Agreements | In January, the company signed an agreement to sell Neurocrine Group Limited and subsidiaries, including the assets and global rights to Alkindi (hydrocortisone oral granules) and the assets and global rights (excluding the United States of America) to Efmody (hydrocortisone modified-release hard capsules) to Immedica Pharma AB. |
| 2025 | Others | In September, the company announced new post-hoc analysis from the KINECT-PRO study, showing symptomatic remission rates for tardive dyskinesia with INGREZZA (valbenazine). |
Competitor Comparison
| Key Parameters | Neurocrine Biosciences Inc | Eli Lilly and Co | Pfizer Inc | Newron Pharmaceuticals SpA | GlaxoSmithKline Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Italy | Canada |
| City | San Diego | Indianapolis | New York City | Bresso | Mississauga |
| State/Province | California | Indiana | New York | - | Ontario |
| No. of Employees | 2,000 | 50,605 | 75,000 | 27 | 1,629 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Rastetter, Ph.D. | Chairman | Executive Board | 2011 | 77 |
| Kyle W. Gano | Director; Chief Executive Officer | Executive Board | 2024 | 53 |
| Matthew C. Abernethy | Chief Financial Officer | Senior Management | 2017 | 46 |
| Lewis Choi | Chief Information Officer | Senior Management | 2025 | - |
| Darin M. Lippoldt | Chief Legal Officer; Secretary | Senior Management | 2014 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer